Characteristics of patients with deletion 17p
. | del(17p)/TP53wt . | del(17p)/TP53mut . | no del(17p) . |
---|---|---|---|
Patients, n | 76 | 45 | 2505 |
Age at diagnosis, median (range), y | 61 (39-71) | 59 (40-71) | 58 (24-72) |
Sex, n (%) | |||
Male | 42 (55) | 25 (56) | 1451 (58) |
Female | 34 (45) | 20 (44) | 1054 (42) |
ISS, n (%) | |||
1 | 18 (29) | 7 (21) | 692 (32) |
2 | 28 (44) | 11 (32) | 950 (45) |
3 | 17 (27) | 16 (47) | 484 (23) |
Patients, n | 63 | 34 | 2126 |
Missing, n | 13 | 11 | 379 |
del(17p), median (range), % | 76 (57-98) | 82 (58-96) | — |
Treatment of multiple myeloma, n (%) | |||
Doublet induction | 26 (34) | 17 (38) | 846 (34) |
Triplet induction | 50 (66) | 28 (62) | 1659 (66) |
Lenalidomide maintenance, n (%) | |||
No | 66 (87) | 36 (80) | 2184 (87) |
Yes | 10 (13) | 9 (20) | 321 (13) |
Survival information | |||
Deaths, n (%) | 39 (51) | 33 (73) | 601 (24) |
Median follow-up (range), mo | 40.5 (1.8-148.4) | 36.0 (3.7-125.4) | 57.8 (1.6-185,2) |
. | del(17p)/TP53wt . | del(17p)/TP53mut . | no del(17p) . |
---|---|---|---|
Patients, n | 76 | 45 | 2505 |
Age at diagnosis, median (range), y | 61 (39-71) | 59 (40-71) | 58 (24-72) |
Sex, n (%) | |||
Male | 42 (55) | 25 (56) | 1451 (58) |
Female | 34 (45) | 20 (44) | 1054 (42) |
ISS, n (%) | |||
1 | 18 (29) | 7 (21) | 692 (32) |
2 | 28 (44) | 11 (32) | 950 (45) |
3 | 17 (27) | 16 (47) | 484 (23) |
Patients, n | 63 | 34 | 2126 |
Missing, n | 13 | 11 | 379 |
del(17p), median (range), % | 76 (57-98) | 82 (58-96) | — |
Treatment of multiple myeloma, n (%) | |||
Doublet induction | 26 (34) | 17 (38) | 846 (34) |
Triplet induction | 50 (66) | 28 (62) | 1659 (66) |
Lenalidomide maintenance, n (%) | |||
No | 66 (87) | 36 (80) | 2184 (87) |
Yes | 10 (13) | 9 (20) | 321 (13) |
Survival information | |||
Deaths, n (%) | 39 (51) | 33 (73) | 601 (24) |
Median follow-up (range), mo | 40.5 (1.8-148.4) | 36.0 (3.7-125.4) | 57.8 (1.6-185,2) |
ISS, International Staging System.